Table 3.
Genotypes/phenotypes/alleles | Patients ANCA+ (n = 151) | Patients ANCA- (n = 36) | Controls (n = 201) | |
CC | 36 | 15 | 92 | |
CT | 87 | 19 | 88 | |
TT | 28 | 2 | 21 | |
CC+CT (vs. TT) | 123 | 34 | 180 | |
TT+CT (vs. CC) | 115 | 21 | 109 | |
C | 159 | 49 | 272 | |
T | 143 | 23 | 130 | |
ANCA+ against ANCA- patients | ANCA+ patients against controls | |||
Genotypes/phenotypes/alleles | ||||
P value | OR (95 % C.I.) | P value | OR (95 % C.I.) | |
CC | 0.03 | 2.3 × 10-5 | ||
CT | 0.10 | 1.91 (0.87 to 4.16)* | 1.6 × 10-4 | 2.53 (1.55 to 4.11)* |
TT | 0.02 | 5.83 (1.23 to 27.65)* | 0.03 | 5.89 (3.01 to 11.53)* |
CC+CT (vs. TT) | 0.07 | 0.26 (0.06 to 1.14) | 0.03 | 0.51 (0.29 to 0.94) |
TT+CT (vs. CC) | 0.03 | 2.26 (1.17 to 4.88) | 2.3 × 10-5 | 2.70 (1.69 to 4.30) |
C | 1.0 × 10-2 | 5.2 × 10-5 | ||
T | 1.91 (1.11 to 3.30) | 1.88 (1.38 to 2.56) |
OR = odds ratio, C.I. = confidence interval.
*Odds ratios for the CT and TT genotypes are contrasted against the CC genotype. No evidence for statistical difference between the ANCA-negative WG patients and the control cohort was revealed, when calculating all off above-used comparisons.